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Abstract
Background: Measurement of the prostate specific antigen (PSA) remains an important tool in prostate cancer (PC)
diagnosis. Due to limited availability of laboratory devices in an outpatient setting, compact and easy-to-handle
point-of-care (POC) systems are desirable. Recently, a chip for PSA measurement on the concile® Ω100 POC reader
platform was introduced. To investigate the clinical applicability, we evaluated the system in a consecutive cohort
of patients undergoing PSA measurement in our outpatient clinic.
Methods: Between 07/2014 and 01/2015, PSA was analyzed in a total of 198 patients by the POC reader system
and in parallel by an Immulite 2000® and Centaur® standard laboratory system, respectively. By standard (Immulite®)
measurement, 67 (34,2 %) had PSA > 4 ng/ml and 131 (65,8 %) had PSA ≤ 4 ng/ml. Results were correlated by linear
regression analyses for all patients and within PSA subgroups. For patients with available prostate histology after
PSA measurement (n = 68), receiver-operating characteristic curves were created and area under the curve (AUC),
sensitivity and specificity for the prediction of PC at best cut-off value were calculated.
Results: The coefficients of determination (r2) for the POC device compared to laboratory testing were 0.72 (Immulite®)
and 0.63 (Centaur®), respectively (both p < 0.0001). In the PSA range of ≤4 ng/ml, the observed correlations were 0.75
and 0.70, respectively. For the POC test system, AUC for detection of PC was calculated with 0.745 while the standard
laboratory tests showed 0.778 (Immulite®) and 0.771 (Centaur®). At best cut-off of 3.64 ng/ml, PSA analysis by the POC
system showed a sensitivity of 85.7 % and a specificity of 66.7 %.
Conclusions: The POC system obtained good concordance to elaborate laboratory measurement. In a screening
scenario, the system provides quick and reliable PSA measurement, especially in the PSA range up to 4 ng/ml.
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Background
Since its discovery in 1979 by Wang et al. [1] prostate
specific antigen (PSA) has become the gold standard
biomarker for screening, diagnosis, and therapeutic
monitoring of prostate cancer (PC), and a routine
clinical parameter for the management of benign hyper-
plasia and inflammatory disorders of the prostate [2–7].
Despite country and health-system dependent ap-
proaches to prostate cancer screening and PSA testing,
patients with clinical symptoms of urinary and prostatic
disorders or the intention to undergo screening for
prostate cancer are often primarily seen and tested for
PSA in an outpatient setting. However, laboratory tests
for PSA are usually performed in centralized institutions
and therefore most often not available in proximity to
the urologists’ or general practitioners’ office, resulting
in a delayed information and putative psychological
discomfort for patients [8].
Point-of-care (POC) test systems for a rapid and reli-
able testing at the practitioners’ office have been already
introduced for several medical conditions. For the evalu-
ation of diabetes or acute inflammation, POC systems
measuring blood count, CRP or HbA1c have shown to
provide reliable test results [9–12].
The present prospective study was performed in order
to evaluate the reproducibility and clinical applicability
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of a novel quantitative POC PSA assay (CancerCheck®
PSA, concile GmbH, Freiburg, Germany) using a port-
able device (concile® Ω100) in comparison to established
standard routine laboratory PSA test systems.
Methods
Patient cohort
We prospectively included 200 patients, who underwent
routine PSA measurement at the University hospital of
Tuebingen. To cover a broad range of PSA values, pa-
tients were recruited based on PSA analysis using the
Immulite® system, which was set as reference method.
We evaluated 150, 25 and 25 patients with PSA values in
the range of ≤4 ng/ml, 4–10 ng/ml and >10 ng/ml. Pa-
tients referred for PC screening, and patients designated
to undergo surgery for PC or lower urinary tract symp-
toms due to benign prostatic hyperplasia were included.
Patients with a history of other urogenital malignancy
were excluded from the study.
Patient samples were prospectively analyzed with two
elaborated test systems, Immulite 2000® (Siemens
Healthcare Diagnostics, Deerfield, USA) and Centaur®
(Siemens Healthcare Diagnostics), and the POC test sys-
tem (CancerCheck® PSA, on the concile® Ω100 reader,
concile GmbH, Freiburg, Germany) in parallel. Blood
samples were collected one day prior to the analyses and
stored at 2–8 °C to provide simultaneous application of
the tests. All three tests were performed within a time-
span of one hour.
Baseline patients’ characteristics (age, history of prior
prostatic disease), subsequent interventions and clinical
parameters after PSA-measurement (biopsy, surgery,
histology) were recorded.
Written informed consent was obtained by all partici-
pants, and the study was approved by the local ethics
committee of the University hospital Tübingen (No.
122/2012BO2).
POC-Test system principle
The POC system consists of a portable device (concile®
Ω100 reader, and a test cassette containing a one-step
chromatographic sandwich immunoassay, which is ana-
lyzed by a charged-couple device (CCD).
After addition of sample, PSA binds to a colloidal
gold-labeled antibody. The resulting complex is captured
by a specific antibody pre-coated at the test zone and
forming a red test line. The concentration of PSA is
measured using complimentary light and the intensity of
the test line is measured by the CCD sensor. The vol-
ume of the signal is directly proportional to the concen-
tration of PSA in the sample and can be measured by
the concile® Ω100 reader with a pre-set calibration
curve. The concentration of PSA is displayed as numeric
result with one decimal place.
Statistics
For data analyses, patients were classified into different
categories of total PSA (tPSA) range ≤4, ≤10 ng/ml and
>10 ng/ml according to the Immulite® measurement.
Linear regression analyses were performed to correlate
individual test results given by the POC reader and
Immulite® and Centaur® measurement in the whole
group and in the three subgroups, respectively. In the
subgroup of patients with available histology, receiver-
operator-characteristics (ROC) analyses were performed
to evaluate the diagnostic performance of the tests with
respect to the correct identification of PC and the area-
under-the-curve (AUC) was calculated. Youden’s index
was used to identify the optimum cut-off for each test
system. Comparison of ROC curves was performed ac-
cording to the method of DeLong. Analyses were per-
formed using commercial software (MedCalc, version
12.5, Ostend, Belgium). Statistical significance was de-
fined as p < 0.05.
Results
Samples of a total of 198 (99 %) patients were available
for the analyses. Two patients were excluded from the
collective due to insufficient sample preparation or ex-
treme PSA values (>800 ng/ml). Median patient age was
66.15 years. Histological workup was performed in 68
patients (34.7 %). Of those, n = 36 (52.2 %) were diag-
nosed with PC. Patients’ characteristics are summarized
in Table 1.
Figure 1 illustrates PSA values determined by POC
concile® measurement compared to the Immulite® (A)
and Centaur® test results (B). The correlation of the
three systems in different PSA ranges is illustrated in
Fig. 2. The coefficient of determination (r2) for the POC
measurement compared to routine lab testing was 0.72
(Immulite®) and 0.63 (Centaur®), respectively. In the PSA
≤4 ng/ml subgroup, r2 were 0.75 (Immulite®) and 0.70
(Centaur®) (both p < 0.0001). For patients with PSA
≤10 ng/ml the coefficients of determination observed
were both 0.88 (Immulite® and Centaur®), respectively. In
the high PSA group of >10 ng/ml, r2 was 0.72 (Immu-
lite®) and 0.70 (Centaur®) (Table 2). With regard to the
correct prediction of prostate cancer, ROC analysis (Fig. 3)
revealed an AUC of 0.745 (95 % CI: 0.625 to 0.843) for the
POC test system, while the AUCs for the standard labora-
tory tests were calculated with 0.778 (95 % CI: 0.661 to
0.870) (Immulite®) and 0.771 (95 % CI: 0.653 to 0.864)
(Centaur®). The comparison of ROC curves revealed no
significant difference between POC and Centaur® meas-
urement, while a significant difference of AUCs from POC
and Immulite® analyses was noted (P = 0.03) (Table 3).
From ROC analysis, optimal PSA cut-off values for the in-
dividual PSA test systems were determined. Sensitivity
and specificity for the detection of prostate cancer and
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optimal PSA cut-off values for the respective test systems
are shown in Table 4. At best cut-off (3.64 ng/ml), the
POC system showed a sensitivity of 85.7 and a specificity
of 66.7, respectively. Table 5 illustrates the association be-
tween PSA at cut-off 4 ng/ml and the presence of PC in
the sub-cohort of patients with available histology. POC
measurement showed the highest negative predictive value
(81.5 %). No further false negative result was observed com-
pared to Immulite®, however two patients (2.9 %) that were
negatively tested in the Centaur® assay were correctly classi-
fied as PC patients by POC measurement.
Within POC measurement, the rate of false positive
subjects at cut-off PSA 4 ng/ml was 16.2 % (n = 11), while
the rates of Centaur® and Immulite® were 11.8 (n = 8) and
19.1 % (n = 13). On the other hand, rates of patients with
a PSA value >4 ng/ml in the Immulite® or Centaur® but
<4 ng/ml in POC analysis were 1.0 % (n = 2, Immulite®)
and 0 % (n = 0, Centaur®), respectively (Table 6).
Discussion
In the present study, we detected a close correlation be-
tween a new POC test system and standard laboratory
tests, as documented by a coefficient of determination of
0.72 for the overall patient population comparing concile®
Ω100 reader and Immulite® measurement. In the clinically
relevant PSA range of ≤4 ng/ml with regard to the predic-
tion of a negative result in a PC screen scenario, the ob-
served correlation was even higher, with r2 of 0.75.
Nevertheless, AUC analysis revealed a higher accuracy
for the established standard assays, which has also been
reported in earlier publications on POC PSA test
systems [13].
However, in urologist’s daily practice it is well known,
that even the established laboratory systems differ in their
results. Therefore, the decision of clinicians whether a bi-
opsy should be recommended or not is dependent on the
PSA system used. Slev et al. analyzed the intermethod dif-
ferences for six different laboratory PSA assays, including
Immulite® and Centaur® and reported relative differences
of more than 10 % at PSA of 4.0 ng/ml [14].
Table 1 Patients’ characteristics
Median patient age, years (Range) 66.15 (42.06–90.09)
Patient groups according to
Immulite® measurement
n= %
≤4 ng/ml 131 65.8 %
>4 ng/ml 67 34.2 %
≤10 ng/ml 168 84.8 %
>10 ng/ml 30 15.2 %
Further diagnostic workup
Histology availablea Yes 69 34.7 %
No 130 65.3 %
Histologic evidence of prostate
cancer
Yes 36 52.2 %
No 30 43.5 %
Median 95 % CI
PSA values Immulite® 2.34 2.07 to 3.10
Centaur® 1.90 1.70 to 2.33
concile® 2.53 2.10 to 3.15
afrom radical prostatectomy, TUR-P, or prostate biopsy
Fig. 1 Illustration of concile® PSA measurement compared to PSA-Immulite®(a) and PSA-Centaur®(b). (for reasons of graphical illustration, two
measurements in the high PSA range are not displayed.)
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Table 2 Results from linear regression analysis
Collective (n = 198) PSA≤ 4 ng/ml (n = 131) PSA≤ 10 ng/ml (n = 161) PSA > 10 ng/ml (n = 37)
r2 P= r2 P= r2 P= r2 P=
Concile® vs. Immulite® 0.7181 <0.0001 0.7518 <0.0001 0.8775 <0.0001 0.7155 <0.0001
Concile® vs. Centaur® 0.6346 <0.0001 0.7037 <0.0001 0.8782 <0.0001 0.7031 <0.0001
Fig. 2 Linear regression analysis of concile® PSA measurement in comparison to Immulite® (a) and Centaur (b) values at PSA range≤ 4 ng/ml
and≤ 10 ng/ml (c, d) (dashed lines = 95 % confidence interval)
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In this context it is noteworthy that a PSA-POC sys-
tem may not provide meticulous correlation to all of the
standard laboratory tests, it should however try to give
the PSA value on a level that is located in an appropriate
range compared to standard assays. A valid variable for
determining this level is the comparison of individual
system’s best cut- offs. With 3.64 ng/ml the POC system
ranged in its level at an adequate best cut-off value.
A PSA value of 4 ng/ml is considered a common
threshold for a biopsy decision. At a cut-off PSA
value of 4 ng/ml, POC measurement outperformed
Immulite® and Centaur® with regard to the negative
predictive value, which underlines the effectiveness of
POC measurement as a screening tool. POC test sys-
tems used at a general practitioners office could be
used as pre-screening tests and avoid unnecessary re-
ferrals to urologists in cases of inconspicuous digital
rectal examintation and low POC PSA values. Despite
the fact, that PSA standard lab test results may in
some cases be available within a few hours according
to specific health system dependent or institutional
conditions, the main rationale for the use of POC
tests is the option to receive a test result within
20 min, which makes a discussion of the test result
with the patient possible in the same session.
As a general rule, POC tests should not be applied as
a diagnostic following radical prostatectomy, where ul-
trasensitive monitoring of PSA is recommended [15, 16].
In patients with POC PSA values in the range of 2.5 to
4.0 ng/ml [17] and beyond, POC measurement should
be regarded as a pre-screening test and an immediate
routine lab testing should follow. In addition, the con-
firmation of an elevated PSA after three weeks, as rec-
ommended by current PC treatment guidelines in cases
of cancer suspicion, should not exclusively been per-
formed by concile® Ω100 measurement [15]. Hence,
POC measurement is subject to the same restrictions in
men undergoing active surveillance for PC. However, the
POC assay appears appropriate for the identification of
patients with a low risk of prostate cancer in the PSA
range of <2.5 ng/ml. The evaluation of other frequent
prostatic diseases like benign hyperplasia, prostatitis,
and follow-up studies for prostate cancer after radiother-
apy or hormonal treatment may also be performed based
on concile® PSA analysis. In PSA ranges >10 ng/ml, up
to extreme PSA values, the diagnostic precision of POC
measurement is impaired. Follow up studies in patients
with extreme PSA values should therefore be performed
with standard assays.
By using PSA POC measurements, the regularly ob-
served delay between PSA sampling, receipt of test re-
sults, and the information and discussion with the
patient may be overcome for a large subgroup of pa-
tients. In a prospective study of 188 patients, Wilkinson
et al. observed that 89 % of patients receiving a rapid re-
sult would prefer to have this method again in order to
facilitate the discussion regarding their future manage-
ment. However, no significant differences between stress
and anxiety of patients receiving PSA test results within
15 min after the test, and 1–4 days after PSA testing
were detected [18].
Handling of the POC system was favorable. While other
one-step POC test systems, usually based on lateral flow
chromatographic immunoassays, could demonstrate
Table 3 Comparison of receiver operator characteristic curves (CI confidence interval, SE a standard error, PSA prostate specific antigen)
Difference between areas Standard error 95 % CI z statistic Significance level
PSA Immulite® vs. PSA concile® 0.0333 0.0162 0.00165 to 0.0650 2062 P = 0.0392
PSA Centaur® vs. PSA concile® 0.026 0.0201 -0.0134 to 0.0654 1293 P = 0.1961
Fig. 3 Comparison of receiver operator chararcteristic curves
resulting from the three test systems
Table 4 Prostate specific antigen best cut-off, sensitivity and
specificity from receiver operator characteristic analysis
Best cut off Sensitivity 95 % CI Specificity 95 % CI
Immulite® 5.02 80.0 63.1–91.6 72.7 54.5–86.7
Centaur® 4.00 80.0 63.1–91.6 75.8 57.7–88.9
Concile® 3.64 85.7 69.7–95.2 66.7 48.2–82.0
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Table 5 Performance of different standard and POC assays at PSA cut-off 4 ng/ml (CI confidence interval, PC prostate cancer, PSA prostate specific antigen, a from chi-square test)
PSA Immulite® PSA Centaur® Concile®
No PC PC No PC PC No PC PC
PSA < 4 20 5 25 (36.8 %) PSA < 4 25 7 32 (47.1 %) PSA < 4 22 5 27 (39.7 %)
PSA≥ 4 13 30 43 (63.2 %) PSA≥ 4 8 28 36 (52.9 %) PSA≥ 4 11 30 41 (60.3 %)
33 (48.50 %) 35 (51.50 %) 68 33 (48.50 %) 35 (51.50 %) 68 33 (48.50 %) 35 (51.50 %) 68
Significance levela P = 0.0002 P < 0.0001 P < 0.0001
95 % CI 95 % CI 95 % CI
Sensitivity 85.71 % 69.74 to 95.19 % 80.00 % 63.06 to 91.56 % 85.71 % 69.74 to 95.19 %
Specificity 60.61 % 42.14 to 77.09 % 75.76 % 57.74 to 88.91 % 66.67 % 48.17 to 82.04 %
Positive predictive value 69.77 % 53.87 to 82.82 % 77.78 % 60.85 to 89.88 % 73.17 % 57.06 to 85.78 %
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practical feasibility and good correlation to routine PSA lab
values [13, 19, 20], earlier studies with semi-quantitative
strip tests for the evaluation of PSA in whole blood, failed
to prove their clinical utility due to impaired test handling
and interpretation [21].
Conclusions
POC measurement with the herein evaluated system al-
lows rapid quantitative analysis of PSA and may help to
circumvent limitations of ambulatory PSA testing for pa-
tients and physicians in need of an immediate test result.
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